Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux

Journal of Pharmaceutical Sciences

Volumn 99, Issue 1, 2010, Pages 413-421

  Suzuki, Toyofumi ^a   Miyata, Mariko ^a   Zaima, Chika ^a   Furuishi, Takayuki ^a   Fukami, Toshiro ^a   Kugawa, Fumihiko ^b   Tomono, Kazuo ^a  

^a NIHON UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Blood brain barrier; Naloxone; P glycoprotein; Transport

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NALOXONE; QUINIDINE; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSPORT; HELA CELL; HUMAN; HUMAN CELL; MALE; MEMBRANE TRANSPORT; MICROINJECTION; NONHUMAN; PARIETAL LOBE; RAT;

EID: 73949118437     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21819     Document Type: Article

References (40)

1. Jaiswal J, Poduri R, Panchagnula R. 1999. Transdermal delivery of naloxone: Ex vivo permeation studies. Int J Pharm 179:129-134.
2. 14C naloxone in the rat and some comparative observations on nalorphine. J Pharmacol Exp Ther 196:257-268.
3. Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S. 1976. Pharmacokinetics of naloxone in rats and in man: Basis for its potency and short duration of action. Anesthesiology 44:398-401.
4. Golden PL, Pollack GM. 2003. Blood-brain barrier efflux transport. J Pharm Sci 92:1739-1753.
5. Sun H, Dai H, Shaik N, Elmquist WF. 2003. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55:83-105.
6. Kusuhara H, Sugiyama Y. 2005. Active efflux across the blood-brain barrier: Role of the solute carrier family. NeuroRx 2:73-85.
7. Löscher W, Potschka H. 2005. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76.
8. Fromm MF. 2004. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423-429.
9. Lin JH. 2004. How significant is the role of Pglycoprotein in drug absorption and brain uptake? Drugs Today (Barc) 40:5-22.
10. Elkiweri IA, Zhang YL, Christians U, Ng KY, Tissot van Patot MC, Henthorn TK. 2009. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: Pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth Analg 108:149-159.
11. Wandel C, Kim R, Wood M, Wood A. 2002. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96:913-920.
12. Dagenais C, Graff CL, Pollack GM. 2004. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276.
13. Rodriguez M, Ortega I, Soengas I, Suarez E, Lukas JC, Calvo R. 2004. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J Pharm Pharmacol 56:367-374.
14. Thompson SJ, Koszdin K, Bernards CM. 2000. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92:1392-1399.
15. Moriki Y, Suzuki T, Furuishi T, Fukami T, Tomono K, Watanabe J. 2005. In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. J Drug Target 13:53-59.
16. Suzuki T, Zaima C, Moriki Y, Fukami T, Tomono K. 2007. P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. J Drug Target 15:67-74.
17. Oldendorf WH. 1970. Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res 24:372-376.
18. Suzuki T, Moriki Y, Goto H, Tomono K, Hanano M, Watanabe J. 2002. Investigation on the influx transport mechanism of pentazocine at the bloodbrain barrier in rats using the carotid injection technique. Biol Pharm Bull 25:1351-1355.
19. Pardridge WM, Fierer G. 1985. Blood-brain barrier transport of butanol and water relative to N-isopropyl-p-iodoamphetamine as the internal reference. J Cereb Blood Flow Metab 5:275-281.
20. Kakee A, Terasaki T, Sugiyama Y. 1996. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 277:1550-1559.
21. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879-885.
22. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F. 2009. Construction of a model cell line for the assay of MDR1 (Multi Drug Resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie 64:296-300.
23. Fishman J, Hahn EF, Norton BI. 1975. Comparative in vivo distribution of opiate agonists and antagonists by means of double isotope techniques. Life Sci 17:1119-1125.
24. Wu D, Kang YS, Bickel U, Pardridge WM. 1997. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos 25:768-771.
25. Bickel U, Schumacher OP, Kang YS, Voigt K. 1996. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther 278: 107-113.
26. Oldendorf WH. 1974. Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med 147:813-815.
27. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. 1972. Blood-brain barrier: Penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178:984-986.
28. Tunblad K, Jonsson EN, Hammarlund-Udenaes M. 2003. Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharm Res 20:618-623.
29. Bouw MR, Gårdmark M, Hammarlund-Udenaes M. 2000. Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats - A microdialysis study. Pharm Res 17: 1220-1227.
30. Weinstein SH, Pfeffer M, Schor JM, Franklin L, Mintz M, Tutko ER. 1973. Absortion and distribution of naloxone in rats after oral and intravenous administration. J Pharm Sci 62:1416-1419.
31. Boström E, Simonsson US, Hammarlund-Udenaes M. 2006. In vivo blood-brain barrier transport of oxycodone in the rat: Indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos 34:1624-1631.
32. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. 2000. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73-79.
33. Hagenbuch B, Meier PJ. 2004. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665.
34. 2,5]-enkephalin at the murine blood-brain barrier by in situ perfusion. Neurosci Lett 301:155-158.
35. Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y. 2008. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 36:2005-2013.
36. Suzuki T, Oshimi M, Tomono K, Hanano M, Watanabe J. 2002. Investigation of transport mechanism of pentazocine across the blood-brain barrier using the in situ rat brain perfusion technique. J Pharm Sci 91:2346-2353.
37. Moriki Y, Suzuki T, Fukami T, Hanano M, Tomono K, Watanabe J. 2004. Involvement of P-glycoprotein in blood-brain barrier transport of pentazocine in rats using brain uptake index method. Biol Pharm Bull 27:932-935.
38. Kusuhara H, Terasaki T, Sugiyama Y. 2003. Brain efflux index method. Characterization of efflux
39. transport across the blood-brain barrier. Methods Mol Med 89:219-231.
40. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.